VanEck Pharmaceutical ETF
PPH
52 hedge funds and large institutions have $188M invested in VanEck Pharmaceutical ETF in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 5 closing their positions.
102% more capital invested
Capital invested by funds: $93.1M → $188M (+$95.3M)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
42.49% more ownership
Funds ownership: 36.88% → 79.37% (+42%)
6% more funds holding
Funds holding: 49 → 52 (+3)
97% less call options, than puts
Call options by funds: $1.12M | Put options by funds: $41.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$84.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$34.1M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$13.8M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.85M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
-$22.9M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$22M |
| 3 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$2.76M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$824K |
| 5 |
OPS
Orion Portfolio Solutions
Omaha,
Nebraska
|
-$288K |
PPH Hedge Fund Activity: Q1 2021 in Review
52 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2021, worth a combined $188M — up 102% from $93.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PPH positions and 5 closed out — a net gain of 4 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $84.5M. The largest seller was Mivtachim The Workers Social Insurance Fund, exiting entirely with an estimated $22.9M sold.
- 52 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2021, up from 49 in Q4 2020.
- Funds reported $188M of VanEck Pharmaceutical ETF stock for Q1 2021, up 102% quarter-over-quarter.
- 9 funds opened new VanEck Pharmaceutical ETF positions in Q1 2021 and 5 closed out, a net change of +4 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2021 was Goldman Sachs, an estimated $84.5M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2021 was Mivtachim The Workers Social Insurance Fund, an estimated $22.9M sold.
Based on aggregated 13F filings for Q1 2021.